Lido Advisors
CRDF icon

Lido Advisors’s Cardiff Oncology CRDF Stock Holding History

Lido Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,000
Closed -$24.3K – 2159
2026
Q1 		$24.3K Buy
15,000
+19
+0.1% +$39 ﹤0.01% 1923
2025
Q4 		$30.9K Hold
14,981
– – ﹤0.01% 1902
2025
Q3 		$30.9K Sell
14,981
-19
-0.1% -$53 ﹤0.01% 1808
2025
Q2 		$47.3K Buy
+15,000
New +$45.8K ﹤0.01% 1620

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Lido Advisors's CRDF Position: Q2 2026 in Review

Lido Advisors sold out of Cardiff Oncology (CRDF) in Q2 2026, closing a stake of 15,000 shares — an estimated $24.3K sold.

Lido Advisors first reported a position in CRDF in Q2 2025 and held it in 4 quarters. The position peaked at $47.3K in Q2 2025. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • Lido Advisors reported no remaining Cardiff Oncology position as of Q2 2026 after selling out during the quarter.
  • Lido Advisors sold 15,000 Cardiff Oncology shares in Q2 2026, an estimated $24.3K.
  • Lido Advisors first reported a position in Cardiff Oncology in Q2 2025 and held it in 4 quarters.
  • Lido Advisors's Cardiff Oncology position peaked at $47.3K in Q2 2025.
  • 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.